Galecto reports $66M cash as of Dec 31, 2022; updates corporate presentation

Damora Therapeutics, Inc.

Cash, cash equivalents, and investments of approx. $66M as of Dec. 31, 2022.
Updated corporate presentation dated Jan. 2023 furnished as an exhibit; no specific details or material changes described.
No financial or operational guidance provided beyond the cash balance update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.